Definium Therapeutics, Inc. (DFTX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Definium Therapeutics, Inc. (formerly Mind Medicine Inc., renamed January 9, 2026) is a late-stage clinical biopharmaceutical company developing novel product candidates for brain health disorders. The company's lead candidates include DT120 (lysergide D-tartrate) for Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), and Posttraumatic Stress Disorder (PTSD), and DT402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(77.1) million | $(23.3) million |
| Operating Expenses | $59.2 million | $32.2 million |
| Research & Development (R&D) | $41.5 million | $23.4 million |
| General & Administrative (G&A) | $17.7 million | $8.8 million |
| Cash & Cash Equivalents | $262.5 million | $82.9 million |
| Short-term Investments | $110.9 million | $153.8 million |
| Total Liquidity (Cash + Investments) | $373.4 million | $236.7 million |
| Long-term Debt (Credit Facility) | $40.8 million | $40.6 million |
| Accumulated Deficit | $(659.8) million | $(422.2) million |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by $53.8 million (230%) compared to Q1 2025. This was primarily driven by a $20.0 million non-cash loss from the change in fair value of 2022 USD Financing Warrants and increased operating expenses.
- Operating Expenses: Total operating expenses rose 84% year-over-year. R&D expenses increased 78% due to accelerated clinical trial activities for the DT120 program (GAD and MDD). G&A expenses doubled (101% increase) due to higher stock-based compensation, personnel costs, and commercial-preparedness expenses.
- Liquidity Position: Cash and cash equivalents increased significantly to $262.5 million, bolstered by the October 2025 public offering which raised approximately $242.8 million in net proceeds. Short-term investments decreased as $42.0 million matured during the quarter.
- Corporate Name Change: The company officially changed its name from Mind Medicine Inc. to Definium Therapeutics, Inc. in January 2026 and now trades under the symbol "DFTX".
Outlook, Guidance, and Risks
- Clinical Milestones:
- DT120 (GAD): The Voyage study is fully enrolled (214 participants); topline data expected in Q3 2026. The Panorama study is fully enrolled (200 participants); topline data expected in late Q3 2026.
- DT120 (MDD): The Emerge study is fully enrolled (149 participants); topline data expected in late Q2 2026. The Ascend study initiated sites in Q1 2026 with dosing expected in Q2 2026.
- DT120 (PTSD): The Haven study is planned for initiation in 2027.
- DT402 (ASD): Phase 2a trial initiated in Q4 2025; initial data anticipated in 2026.
- Cash Runway: Management believes current cash, cash equivalents, and investments ($373.4 million) are sufficient to fund operations into 2028.
- Debt Covenants: The company has an Amended Loan Agreement with K2 HealthVentures LLC. A minimum liquidity covenant applies beginning July 1, 2026, unless market capitalization exceeds $500 million or specific fundraising milestones are met.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital if milestones are not met, regulatory hurdles regarding Schedule I controlled substances (DEA rescheduling), and potential dilution from future equity financings.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $42.6 million operating cash outflow for Q1 2026 against the projected runway into 2028.
- Warrant Liability Volatility: Monitor the fair value of the 2022 USD Financing Warrants, which caused a $20.0 million non-cash loss in Q1 2026 and can significantly distort net loss figures.
- Clinical Enrollment Status: Confirm the status of the Voyage, Panorama, and Emerge studies to ensure topline data readouts in Q2/Q3 2026 remain on schedule.
- Debt Covenant Compliance: Review the company's market capitalization and liquidity levels as of July 1, 2026, to ensure compliance with the minimum liquidity covenant in the Amended Loan Agreement.
- Regulatory Rescheduling: Track any updates from the DEA regarding the rescheduling of lysergide (LSD) and MDMA, which is critical for commercialization in the U.S.